The European Patent Office (EPO) has published patent application EP4709413A1, detailing a combination vaccine developed by Intervet International B.V. The patent application, published on March 18, 2026, specifically covers a vaccine formulation designed to provide immunity against three distinct pathogens: Erysipelothrix rhusiopathiae, Porcine Parvo virus, and Leptospira bacterium. The application lists Antonius Arnoldus Christiaan Jacobs as the inventor and includes IPC classifications related to vaccines and infectious disease treatment.

This publication represents the granting of a patent for a novel veterinary vaccine. While this is a patent publication and not a regulatory rule, it signifies intellectual property protection for a new product in the animal health sector. Companies involved in veterinary pharmaceuticals and vaccine development should note this patent as it may impact market exclusivity and competitive landscape for products targeting these specific diseases in swine and potentially other animals. No immediate compliance actions are required for regulated entities based solely on this patent publication.